Astria Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Astria Therapeutics, Inc. stockholders will vote on a proposed merger with BioCryst Pharmaceuticals, Inc., offering a mix of cash and stock valued at a premium.
Astria Therapeutics will hold its annual stockholders meeting on June 11, 2025, to elect directors, approve a stock incentive plan amendment, ratify the appointment of Ernst & Young LLP, and conduct an advisory vote on executive compensation.
Astria Therapeutics is holding its 2025 Annual Meeting of Stockholders on June 11, 2025, to vote on key proposals including the election of directors and an amendment to the company's stock incentive plan.
Astria Therapeutics will hold its annual stockholders meeting on June 5, 2024, to vote on director elections, a stock incentive plan amendment, auditor ratification, and executive compensation.
Astria Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on director elections, an amended stock incentive plan, ratification of the accounting firm, and executive compensation.